DIMA Biotechnology LTD is a research and development company of recombinant monoclonal antibody focusing on immune oncology products and services. DIMA’s proprietary B cell cloning and recombinant monoclonal antibody development platform, DimAb®, can efficiently generate high-quality monoclonal antibodies in high throughput. The R&D team has many years of experience in monoclonal antibody development. We provide solutions for scientific research, clinical diagnosis and therapeutic R&D.
The corporate culture is integrity, pragmatism, innovation and focus. The mission for the company is to apply advanced biotechnology to provide new and effective solutions for cancer diagnosis and treatment.